Is PLRX or IMRX more profitable?

Immuneering's return on equity of -27.15% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Immuneering N/A -27.15% -25.75%

Is PLRX or ALXO more profitable?

Pliant Therapeutics' return on equity of -58.11% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% ALX Oncology N/A -90.30% -67.28%

Is PLRX or ELDN more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Eledon Pharmaceuticals N/A -116.97% -41.91%

Pliant Therapeutics (PLRX) Competitors

$1.04 -0.01 (-0.95%)

As of 08/10/2026 04:00 PM Eastern

Compare

PLRX vs. TKNO, FATE, IMRX, ALXO, and ELDN

Should you buy Pliant Therapeutics stock or one of its competitors? Pliant Therapeutics's main competitors and comparable companies include Alpha Teknova (TKNO), Fate Therapeutics (FATE), Immuneering (IMRX), ALX Oncology (ALXO), and Eledon Pharmaceuticals (ELDN). Companies are selected based on similarities in market, industry, and size.

How does Pliant Therapeutics compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Pliant Therapeutics has a net margin of 0.00% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
Pliant Therapeutics	N/A	-58.11%	-44.37%

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 13.2% of Alpha Teknova shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alpha Teknova has higher revenue and earnings than Pliant Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	8.89	-$17.26M	-$0.31	N/A
Pliant Therapeutics	$1.58M	40.76	-$149.34M	-$1.84	N/A

Alpha Teknova has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Alpha Teknova currently has a consensus target price of $7.00, suggesting a potential upside of 4.17%. Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 188.46%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Alpha Teknova had 15 more articles in the media than Pliant Therapeutics. MarketBeat recorded 15 mentions for Alpha Teknova and 0 mentions for Pliant Therapeutics. Alpha Teknova's average media sentiment score of 0.64 beat Pliant Therapeutics' score of 0.00 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Positive
Pliant Therapeutics	Neutral

Summary

Alpha Teknova beats Pliant Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Fate Therapeutics had 3 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Fate Therapeutics and 0 mentions for Pliant Therapeutics. Fate Therapeutics' average media sentiment score of 0.51 beat Pliant Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Fate Therapeutics	Positive
Pliant Therapeutics	Neutral

Fate Therapeutics currently has a consensus target price of $5.13, suggesting a potential upside of 85.69%. Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 188.46%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fate Therapeutics has higher revenue and earnings than Pliant Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	48.38	-$136.32M	-$1.09	N/A
Pliant Therapeutics	$1.58M	40.76	-$149.34M	-$1.84	N/A

Pliant Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Pliant Therapeutics' return on equity of -58.11% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Pliant Therapeutics	N/A	-58.11%	-44.37%

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Fate Therapeutics beats Pliant Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to Immuneering?

Pliant Therapeutics (NASDAQ:PLRX) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Pliant Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Pliant Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 188.46%. Immuneering has a consensus target price of $17.50, indicating a potential upside of 286.31%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Immuneering had 20 more articles in the media than Pliant Therapeutics. MarketBeat recorded 20 mentions for Immuneering and 0 mentions for Pliant Therapeutics. Immuneering's average media sentiment score of 0.83 beat Pliant Therapeutics' score of 0.00 indicating that Immuneering is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Immuneering	Positive

Immuneering has lower revenue, but higher earnings than Pliant Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	40.76	-$149.34M	-$1.84	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Immuneering's return on equity of -27.15% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Immuneering	N/A	-27.15%	-25.75%

Summary

Immuneering beats Pliant Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to ALX Oncology?

Pliant Therapeutics (NASDAQ:PLRX) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Pliant Therapeutics' return on equity of -58.11% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
ALX Oncology	N/A	-90.30%	-67.28%

ALX Oncology has lower revenue, but higher earnings than Pliant Therapeutics. ALX Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	40.76	-$149.34M	-$1.84	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Pliant Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Pliant Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 188.46%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 123.30%. Given Pliant Therapeutics' higher possible upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, ALX Oncology had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 4 mentions for ALX Oncology and 0 mentions for Pliant Therapeutics. ALX Oncology's average media sentiment score of 0.71 beat Pliant Therapeutics' score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
ALX Oncology	Positive

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 12.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ALX Oncology beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Pliant Therapeutics (NASDAQ:PLRX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 188.46%. Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 162.68%. Given Pliant Therapeutics' higher possible upside, research analysts clearly believe Pliant Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eledon Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	40.76	-$149.34M	-$1.84	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pliant Therapeutics' return on equity of -58.11% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Pliant Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Eledon Pharmaceuticals	Neutral

Summary

Eledon Pharmaceuticals beats Pliant Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$65.02M	$3.70B	$7.01B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.07%
P/E Ratio	-0.57	9.09	269.20	24.72
Price / Sales	40.76	1,265.42	592.83	98.22
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.35	18.00	11.39	6.42
Net Income	-$149.34M	-$13.25M	$3.45B	$347.03M
7 Day Performance	-0.95%	3.10%	1.92%	0.69%
1 Month Performance	-7.14%	-1.68%	-0.57%	-0.90%
1 Year Performance	-38.82%	61.75%	75.49%	21.87%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	1.7802 of 5 stars	$1.04 -1.0%	$3.00 +188.5%	-37.3%	$65.02M	$1.58M	N/A	90
TKNO Alpha Teknova	1.2869 of 5 stars	$5.01 +3.2%	N/A	+58.9%	$267.75M	$41.80M	N/A	240	Earnings Report Analyst Upgrade
FATE Fate Therapeutics	3.1482 of 5 stars	$2.28 -6.4%	$5.13 +125.3%	+199.5%	$265.17M	$6.65M	N/A	550	News Coverage
IMRX Immuneering	3.3313 of 5 stars	$4.10 -6.0%	$17.57 +328.9%	+39.4%	$264.62M	N/A	N/A	60	Earnings Report Upcoming Earnings Analyst Revision
ALXO ALX Oncology	2.2766 of 5 stars	$1.96 -3.2%	$4.60 +135.3%	+204.4%	$261.73M	N/A	N/A	40	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. TKNO, FATE, IMRX, ALXO, and ELDN

How does Pliant Therapeutics compare to Alpha Teknova?

Summary

How does Pliant Therapeutics compare to Fate Therapeutics?

Summary

How does Pliant Therapeutics compare to Immuneering?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Summary

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. TKNO, FATE, IMRX, ALXO, and ELDN

How does Pliant Therapeutics compare to Alpha Teknova?

Is TKNO or PLRX more profitable?

Do institutionals & insiders have more ownership in TKNO or PLRX?

Which has higher valuation and earnings, TKNO or PLRX?

Which has more volatility & risk, TKNO or PLRX?

Do analysts recommend TKNO or PLRX?

Does the media prefer TKNO or PLRX?

Summary

How does Pliant Therapeutics compare to Fate Therapeutics?

Which has more risk & volatility, FATE or PLRX?

Does the media prefer FATE or PLRX?

Do analysts rate FATE or PLRX?

Which has stronger earnings & valuation, FATE or PLRX?

Is FATE or PLRX more profitable?

Do institutionals and insiders have more ownership in FATE or PLRX?

Summary

How does Pliant Therapeutics compare to Immuneering?

Which has more volatility & risk, PLRX or IMRX?

Do analysts rate PLRX or IMRX?

Does the media favor PLRX or IMRX?

Which has better earnings and valuation, PLRX or IMRX?

Do institutionals and insiders believe in PLRX or IMRX?

Is PLRX or IMRX more profitable?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Is PLRX or ALXO more profitable?

Which has preferable earnings & valuation, PLRX or ALXO?

Which has more volatility and risk, PLRX or ALXO?

Do analysts prefer PLRX or ALXO?

Does the media favor PLRX or ALXO?

Do institutionals and insiders have more ownership in PLRX or ALXO?

Summary

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Do analysts rate PLRX or ELDN?

Which has stronger earnings and valuation, PLRX or ELDN?

Do insiders & institutionals hold more shares of PLRX or ELDN?

Is PLRX or ELDN more profitable?

Which has more volatility and risk, PLRX or ELDN?

Does the media prefer PLRX or ELDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools